InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
ZenNavigator54 Free
04/20/24 12:18 AM
profile icon
ZenNavigator54 Free
04/20/24 12:16 AM
profile icon
cowtown jay Free
04/19/24 7:37 PM
profile icon
shajandr Free
04/19/24 12:30 PM
profile icon
ZenNavigator54 Free
04/19/24 12:12 AM
profile icon
DTGoody Grandfathered
04/18/24 11:40 PM
Bullish
Bullish
profile icon
ZenNavigator54 Free
04/18/24 11:23 PM
profile icon
dloggold Free
04/18/24 11:11 PM
profile icon
ZenNavigator54 Free
04/18/24 11:03 PM
profile icon
ZenNavigator54 Free
04/18/24 11:02 PM
profile icon
DTGoody Grandfathered
04/18/24 9:01 PM
Bullish
Bullish
profile icon
dloggold Free
04/18/24 6:53 PM
profile icon
DTGoody Grandfathered
04/18/24 6:47 PM
Bullish
Bullish
profile icon
sosjtb Free
04/18/24 11:09 AM
profile icon
DTGoody Grandfathered
04/17/24 10:42 PM
Bullish
Bullish
profile icon
cowtown jay Free
04/17/24 2:28 PM
profile icon
cowtown jay Free
04/16/24 11:28 PM
profile icon
gringhez Free
04/16/24 3:20 PM
profile icon
ZenNavigator54 Free
04/16/24 10:25 AM
profile icon
ZenNavigator54 Free
04/16/24 10:23 AM
profile icon
cowtown jay Free
04/16/24 9:15 AM

Humanigen Inc (fka HGENQ) RSS Feed

Followers
326
Posters
943
Posts (Today)
0
Posts (Total)
43443
Created
01/31/13
Type
Free
Moderators cowtown jay

https://www.humanigen.com/
 

COMPANY OVERVIEW

Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms.  As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.

We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective.  In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.

The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate.  A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma.  The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.  The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT.  The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline. 
 

Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19

May 28, 2021 09:00 AM Eastern Daylight Time

https://www.businesswire.com/news/home/20210528005244/en/Humanigen-Submits-Application-to-FDA-for-Emergency-Use-Authorization-for-Lenzilumab-in-COVID-19 
 


Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind Placebo-Controlled Study Demonstrating the Efficacy and Safety of Lenzilumab™ in Hospitalized COVID-19 Patients

https://finance.yahoo.com/news/humanigen-announces-publication-results-phase-155300197.html

Humanigen's Lenzilumab With CAR T-Cell Therapy Improves Response in Lymphoma

https://www.precisiononcologynews.com/cancer/humanigens-lenzilumab-car-t-cell-therapy-improves-response-lymphoma#.YKFqsahKhcU
 


Mayo Clinic Study of Humanigen’s Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients

June 15, 2020

https://www.businesswire.com/news/home/20200615005324/en/Mayo-Clinic-Study-Humanigen%E2%80%99s-Lenzilumab-Shows-Rapid


Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia 

https://clinicaltrials.gov/ct2/show/NCT04351152 

Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets


https://www.clinicaltrialsarena.com/comment/anti-gm-csf-antibodies-covid-19/ 
 
National Institutes of Health Selects Humanigen’s Lenzilumab for its COVID-19 Big Effect Trial







 
Board Info
Posts Today
0
Posts (Total)
43443
Posters
943
Moderators
New Post